<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Allergy Clin Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Allergy Clin. Immunol</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Allergy and Clinical Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0091-6749</issn>
      <issn pub-type="epub">1097-6825</issn>
      <publisher>
        <publisher-name>Mosby</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24679846</article-id>
      <article-id pub-id-type="pmc">4085475</article-id>
      <article-id pub-id-type="publisher-id">S0091-6749(14)00185-7</article-id>
      <article-id pub-id-type="doi">10.1016/j.jaci.2013.12.1093</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKK&#x3B2;<sup><xref ref-type="fn" rid="d32e359">&#x2606;</xref></sup></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Burns</surname>
            <given-names>Siobhan O.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <email>siobhan.burns@ucl.ac.uk</email>
          <email>sn262@cam.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Plagnol</surname>
            <given-names>Vincent</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gutierrez</surname>
            <given-names>Beatriz Morillo</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Al Zahrani</surname>
            <given-names>Daifulah</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Curtis</surname>
            <given-names>James</given-names>
          </name>
          <degrees>BSc</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaspar</surname>
            <given-names>Miguel</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hassan</surname>
            <given-names>Amel</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>Alison M.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malone</surname>
            <given-names>Marian</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rampling</surname>
            <given-names>Dyanne</given-names>
          </name>
          <degrees>FIBMS</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McLatchie</surname>
            <given-names>Alex</given-names>
          </name>
          <degrees>BSc</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Doffinger</surname>
            <given-names>Rainer</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gilmour</surname>
            <given-names>Kimberly C.</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Henriquez</surname>
            <given-names>Frances</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thrasher</surname>
            <given-names>Adrian J.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaspar</surname>
            <given-names>H. Bobby</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff6" ref-type="aff">f</xref>
          <xref rid="fn1" ref-type="fn">&#x2217;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nejentsev</surname>
            <given-names>Sergey</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
          <xref rid="fn1" ref-type="fn">&#x2217;</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Institute of Immunity and Transplantation, University College London, and the Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom</aff>
      <aff id="aff2"><label>b</label>Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom</aff>
      <aff id="aff3"><label>c</label>UCL Genetics Institute, UCL, London, United Kingdom</aff>
      <aff id="aff4"><label>d</label>Department of Pediatrics, King Abdulaziz Medical City, Jeddah, Saudi Arabia</aff>
      <aff id="aff5"><label>e</label>Department of Medicine, University of Cambridge, Cambridge, United Kingdom</aff>
      <aff id="aff6"><label>f</label>Molecular Immunology Unit, Institute of Child Health, University College London, London, United Kingdom</aff>
      <author-notes>
        <fn id="fn1">
          <label>&#x2217;</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>134</volume>
      <issue>1</issue>
      <fpage>215</fpage>
      <lpage>218.e3</lpage>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p content-type="salutation">To the Editor:</p>
    <p>Nuclear factor kappa B (NF-&#x3BA;B) signaling is known to be important for host protection against infection. For activation, proteins of the NF-&#x3BA;B transcription factor must be released from constitutive interaction with inhibitory I&#x3BA;B proteins (I&#x3BA;B&#x3B1;, I&#x3BA;B&#x3B2;, and I&#x3BA;B&#x3B5;), which sequester NF-&#x3BA;B complexes in the cytoplasm. This occurs through phosphorylation and degradation of I&#x3BA;B proteins by the upstream I&#x3BA;B kinase (IKK) complex, for example, following stimulation of cell surface receptors. The IKK complex consists of 2 catalytically active kinases, IKK&#x3B1; and IKK&#x3B2;, and the regulatory subunit IKK&#x3B3;, also known as NF-&#x3BA;B essential modulator (NEMO). In the canonical pathway of NF-&#x3BA;B activation, I&#x3BA;B&#x3B1; undergoes IKK&#x3B2;-dependent phosphorylation and ubiquitin-mediated degradation, liberating the NF-&#x3BA;B heterodimer, which then translocates to the nucleus.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Mutations in 2 proteins of the NF-&#x3BA;B signaling pathway, NEMO and I&#x3BA;B&#x3B1;, have been described in humans and result in immunodeficiency (ID), usually associated with ectodermal dysplasia (EDA). Hypormorphic hemizygote NEMO mutations cause X-linked EDA-ID, while hypermorphic I&#x3BA;B&#x3B1; mutations lead to an autosomal-dominant EDA-ID.<xref rid="bib2 bib3 bib4" ref-type="bibr"><sup>2-4</sup></xref> Affected individuals are susceptible to severe infections with pyogenic bacteria and mycobacteria and in some cases opportunistic and viral pathogens.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> In addition, an autosomal-recessive mutation in IKK&#x3B1; has been associated with an <italic>in utero</italic> lethal Cocoon syndrome characterized by multiple fetal malformations.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p>
    <p>Here, we report an 18-month-old female, second child of first-degree consanguineous parents from the Arabian Peninsula (see <xref rid="dfig1" ref-type="fig">Fig E1</xref>, <italic>A</italic>, in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0010">www.jacionline.org</ext-link>), who presented at age 2 months with omphalitis and delayed separation of the umbilical cord, necessitating surgical removal. At age 3 months, she developed Salmonella sepsis and subsequently suffered severe recurrent infections caused by a range of organisms including <italic>Acinetobacter</italic>, <italic>Enterobacter</italic>, <italic>Stenotrophomonas</italic>, and <italic>Achromobacter</italic> species, rotavirus, and <italic>Candida</italic>. Chronic diarrhea and a generalized maculopapular rash were persistent from the neonatal period. Disseminated BCGosis was diagnosed from skin and gut biopsies, and antimycobacterial treatment started at age 4 months. Her family history was significant for a brother who had died at age 1 month from <italic>E coli</italic> sepsis and meningitis. In addition, 3 paternal grand uncles had died in infancy with short febrile illnesses.</p>
    <p>At the age of 18 months, our patient had conical teeth, hepatosplenomegaly, and a severe skin rash (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>A</italic> and <italic>B</italic>). This was confirmed to be persistent BCGosis on skin biopsy showing a mixed inflammatory infiltrate and possible epithelioid granuloma formation (<xref rid="dfig1" ref-type="fig">Fig E1</xref>, <italic>B</italic>), with acid-fast bacilli visible and a PCR positive for DNA of <italic>Mycobacterium tuberculosis</italic> complex, but negative for the <italic>esat-6</italic> gene. Initial immunology investigations demonstrated normal proportions and numbers of naive and memory T, B, and natural killer cells, normal T-cell repertoire, and T-cell proliferation to PHA (<xref rid="tbl1" ref-type="table">Table I</xref>). Expression of MHC class II molecules was preserved. Neutrophil number, respiratory burst, and integrin expression were normal, as was phenotyping for monocytes and dendritic cell populations. Immunoglobulin levels had been documented to be low on repeated sampling at age 3 months (IgG 1.2 g/L, IgA&#xA0;&lt; 0.05 g/L, and IgM&#xA0;&lt;&#xA0;0.05 g/L) and therefore immunoglobulin replacement had already been commenced. Liver function test results were normal (including aspartate transaminase, gamma-glutamyl transpeptidase, alkaline phosphatase, albumin, total protein, and total bilirubin levels). Whole blood cytokine assays on 2 occasions demonstrated severely impaired production of IFN-&#x3B3; to all stimuli, absent production of IL-17, and a markedly reduced production of the proinflammatory cytokines, TNF-&#x3B1; and&#xA0;IL-6, in response to a range of Toll-like receptor ligands (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>C</italic>). Stimulated IL-12 production was also reduced and&#xA0;not significantly rescued by addition of exogenous IFN-&#x3B3;. The pattern of cytokine response and clinical features were not consistent with a classical IL-12/INF-&#x3B3; pathway defect but would be consistent with a defect in the NF-&#x3BA;B pathway.</p>
    <p>Our patient<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> was treated with ethambutol, rifampicin, isoniazid, and pyridoxine as well as prophylactic azithromycin, fluconazole, and intravenous immunoglobulin in view of her immunodeficiency. INF-&#x3B3; treatment was added at 50 &#x3BC;g/m<sup>2</sup> and gradually increased to 200 &#x3BC;g/m<sup>2</sup>.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> This was not well tolerated, and she developed ulcerating skin inflammation and increasing hepatosplenomegaly necessitating low-dose steroid treatment (0.5 mg/kg) and therefore IFN-&#x3B3; treatment was withdrawn. She continued to have recurrent episodes of fever and increased inflammatory markers that most likely reflected her BCGosis. She subsequently developed a progressive respiratory distress, was admitted to intensive care for noninvasive ventilation, and, unexpectedly, died from a massive gastrointestinal and pulmonary hemorrhage after a surgical central line insertion at age 25 months.</p>
    <p>To identify the causative mutation, we used exome sequencing. Blood sample of the patient was obtained with informed consent from the parents in accordance with the Declaration of Helsinki and with approval from the ethics committees (04/Q0501/119 and 06/Q0508/16). Library preparation, exome capture, and sequencing have been done according to the manufactures instructions. For exome target enrichment, Agilent SureSelect 50 Mb kit was used. Sequencing was done using Illumina HiSeq with 94 bp paired-end reads. In the exome data, we found 22,754 single-nucleotide variants and small insertions/deletions, including 172 very rare ones, that is, those not seen in the 1000 Genomes database (April 2012 data release) and our internal databases. Five of these variants were homozygous (see <xref rid="tblE1" ref-type="table">Table E1</xref> in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0015">www.jacionline.org</ext-link>). Among these we identified a homozygous nonsense mutation c.321C&gt;A in the <italic>IKBKB</italic> gene that encodes the IKK&#x3B2; protein, leading to a premature stop codon p.Y107X (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>D</italic>; see <xref rid="dfig2" ref-type="fig">Fig E2</xref>, <italic>A</italic>, in this article's Online Repository at <ext-link ext-link-type="uri" xlink:href="http://www.jacionline.org" id="intref0020">www.jacionline.org</ext-link>). In the exome sequence data, we found no mutations in genes encoding I&#x3BA;B&#x3B1;, NEMO, or other proteins of the NF-&#x3BA;B pathway. Because gene <italic>IKBKG</italic> that encodes NEMO was poorly covered in the exome data, we studied it by Sanger sequencing and again found no mutations. We then confirmed the <italic>IKBKB</italic> mutation by Sanger sequencing and showed that both parents were heterozygous carriers of this mutation (<xref rid="dfig2" ref-type="fig">Fig E2</xref>, <italic>B</italic>). We then purified proteins from PBMCs and demonstrated that the patient completely lacked IKK&#x3B2; expression (<xref rid="fig1" ref-type="fig">Fig 1</xref>, <italic>E</italic>). We used polyclonal rabbit anti-IKK&#x3B2; antibody (Cell Signaling Technology cat no. 2678) produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu570 of the 756 amino acid IKK&#x3B2; protein. Therefore, presence of a shorter IKK&#x3B2; protein that potentially could be generated after reinitiation of translation seems unlikely. Further functional experiments were not possible, because no patient-derived cell lines were available after the patient's death. Given that functional reconstitution experiments were impossible, we cannot formally prove that the IKK&#x3B2; deficiency has caused the immune phenotype of the patient, although it is very likely in the absence of other candidate loss-of-function mutations. However, additional unknown modifier genetic or nongenetic factors may have affected the severity of the patient's phenotype.</p>
    <p>Here we demonstrate that an autosomal-recessive human IKK&#x3B2; deficiency has a clinical presentation, which resembles both hypermorphic I&#x3BA;B&#x3B1; and hypomorphic NEMO mutations, with a prominent susceptibility to mycobacteria and an increased frequency of other bacterial infections. No loss-of-function alleles in the <italic>IKBKB</italic> gene were previously found in up to 6500 healthy subjects (National Heart, Lung, and Blood Institute exome variant server, accessed May 2013), suggesting that such mutations are likely to be pathogenic. Recently, a conference abstract has been published describing a group of patients with severe combined immunodeficiency with agammaglobulinemia that were associated with a frameshift mutation in the <italic>IKBKB</italic> gene, which apparently led to an abolished IKK&#x3B2; expression.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> In contrast to our patient, they had reduced numbers of natural killer cells and manifested with invasive bacterial and viral, but not mycobacterial, infections. Furthermore, no ectodermal dysplasia was reported, which distinguishes them from our patient and most patients with NEMO and I&#x3BA;B&#x3B1; mutations.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The reasons for such discrepancies should be clarified when a more detailed description of those patients is published.</p>
    <p>The IKK&#x3B2;-deficient mouse embryos die because of liver degeneration and apoptosis.<xref rid="bib9 bib10 bib11" ref-type="bibr"><sup>9-11</sup></xref> In contrast, our data suggest that humans with the IKK&#x3B2; deficiency can be viable. This is potentially explained by the compensatory mechanisms involving IKK&#x3B1; and the noncanonical pathway of NF-&#x3BA;B activation that are unlikely to be affected by the IKK&#x3B2; deficiency. Interestingly, while NF-&#x3BA;B activation in cells of the IKK&#x3B2;-deficient mice was significantly impaired, it was not completely abolished, as residual signaling was mediated by IKK&#x3B1;.<xref rid="bib9 bib10" ref-type="bibr"><sup>9,10</sup></xref> In the absence of IKK&#x3B2;, IKK&#x3B1; can make homodimers, which can bind NEMO and phosphorylate I&#x3BA;B&#x3B1;, thus partially compensating for the loss of the IKK&#x3B1;/IKK&#x3B2; heterodimers.<xref rid="bib9 bib12" ref-type="bibr"><sup>9,12</sup></xref> We did not observe significant biochemical liver disease in our patient, which may also relate to compensatory mechanisms or result from species variation.</p>
    <p>The severe granulomatous reaction seen in our patient may be a feature of systemic infection.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> However, altered keratinocyte function may additionally cause skin inflammation because mice with epidermis-specific deletion of IKK&#x3B2; develop a severe TNF-mediated inflammatory skin disease.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Our patient had chronic diarrhea, similar to most of the patients with the I&#x3BA;B&#x3B1; mutations. This is consistent with the importance of the NF-&#x3BA;B pathway for mucosal immunity, maintaining intestinal epithelia integrity and homeostasis in the gut.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> In line with other defects of NF-&#x3BA;B signaling, hypogammaglobulinemia and ectodermal dysplasia, characterized by peg teeth, were features of IKK&#x3B2; deficiency in our case. The immunological phenotype was characterized by a profound defect in the production of proinflammatory cytokines despite intact development of all immune cell lineages. Although the clinical spectrum of the condition will be clarified by the identification of other affected families, the severity of immunodeficiency in our patient and failure to respond to conservative therapy suggest that bone marrow transplantation should be considered for children with complete IKK&#x3B2; deficiency.</p>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sref1">
          <person-group person-group-type="author">
            <name>
              <surname>Oeckinghaus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hayden</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Crosstalk in NF-kappaB signaling pathways</article-title>
          <source>Nat Immunol</source>
          <volume>12</volume>
          <year>2011</year>
          <fpage>695</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">21772278</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sref2">
          <person-group person-group-type="author">
            <name>
              <surname>Doffinger</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Smahi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bessia</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Geissmann</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Feinberg</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Durandy</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling</article-title>
          <source>Nat Genet</source>
          <volume>27</volume>
          <year>2001</year>
          <fpage>277</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="pmid">11242109</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sref3">
          <person-group person-group-type="author">
            <name>
              <surname>Filipe-Santos</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Bustamante</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Haverkamp</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Vinolo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Puel</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production</article-title>
          <source>J Exp Med</source>
          <volume>203</volume>
          <year>2006</year>
          <fpage>1745</fpage>
          <lpage>1759</lpage>
          <pub-id pub-id-type="pmid">16818673</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sref4">
          <person-group person-group-type="author">
            <name>
              <surname>Courtois</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Smahi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Reichenbach</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Doffinger</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cancrini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bonnet</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency</article-title>
          <source>J Clin Invest</source>
          <volume>112</volume>
          <year>2003</year>
          <fpage>1108</fpage>
          <lpage>1115</lpage>
          <pub-id pub-id-type="pmid">14523047</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sref5">
          <person-group person-group-type="author">
            <name>
              <surname>Picard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Puel</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency</article-title>
          <source>Clin Microbiol Rev</source>
          <volume>24</volume>
          <year>2011</year>
          <fpage>490</fpage>
          <lpage>497</lpage>
          <pub-id pub-id-type="pmid">21734245</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sref6">
          <person-group person-group-type="author">
            <name>
              <surname>Lahtela</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nousiainen</surname>
              <given-names>H.O.</given-names>
            </name>
            <name>
              <surname>Stefanovic</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Tallila</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Viskari</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Karikoski</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Mutant CHUK and severe fetal encasement malformation</article-title>
          <source>N Engl J Med</source>
          <volume>363</volume>
          <year>2010</year>
          <fpage>1631</fpage>
          <lpage>1637</lpage>
          <pub-id pub-id-type="pmid">20961246</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sref7">
          <person-group person-group-type="author">
            <name>
              <surname>Alangari</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Al-Zamil</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Al-Mazrou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Al-Muhsen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Boisson-Dupuis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Awadallah</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of disseminated mycobacterial infection with high-dose IFN-gamma in a patient with IL-12Rbeta1 deficiency</article-title>
          <source>Clin Dev Immunol</source>
          <volume>2011</volume>
          <year>2011</year>
          <fpage>691956</fpage>
          <pub-id pub-id-type="pmid">21234109</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sref8">
          <person-group person-group-type="author">
            <name>
              <surname>Pannicke</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Baumann</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Fuchs</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rensing-Ehl</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Holzmann</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Henneke</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A novel SCID due to an IKBKB defect</article-title>
          <source>J Clin Immunol</source>
          <volume>32</volume>
          <year>2012</year>
          <fpage>S381</fpage>
          <lpage>S382</lpage>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sref9">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Van</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Mercurio</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K.F.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>I.M.</given-names>
            </name>
          </person-group>
          <article-title>Severe liver degeneration in mice lacking the IkappaB kinase 2 gene</article-title>
          <source>Science</source>
          <volume>284</volume>
          <year>1999</year>
          <fpage>321</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="pmid">10195897</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sref10">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fuentes</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Durnin</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Dalrymple</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice</article-title>
          <source>Immunity</source>
          <volume>10</volume>
          <year>1999</year>
          <fpage>421</fpage>
          <lpage>429</lpage>
          <pub-id pub-id-type="pmid">10229185</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sref11">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Z.W.</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Delhase</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deerinck</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ellisman</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis</article-title>
          <source>J Exp Med</source>
          <volume>189</volume>
          <year>1999</year>
          <fpage>1839</fpage>
          <lpage>1845</lpage>
          <pub-id pub-id-type="pmid">10359587</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sref12">
          <person-group person-group-type="author">
            <name>
              <surname>Woronicz</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Rothe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Goeddel</surname>
              <given-names>D.V.</given-names>
            </name>
          </person-group>
          <article-title>IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK</article-title>
          <source>Science</source>
          <volume>278</volume>
          <year>1997</year>
          <fpage>866</fpage>
          <lpage>869</lpage>
          <pub-id pub-id-type="pmid">9346485</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sref13">
          <person-group person-group-type="author">
            <name>
              <surname>Samaniego</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Marcu</surname>
              <given-names>K.B.</given-names>
            </name>
          </person-group>
          <article-title>IKKbeta in myeloid cells controls the host response to lethal and sublethal Francisella tularensis LVS infection</article-title>
          <source>PLoS One</source>
          <volume>8</volume>
          <year>2013</year>
          <fpage>e54124</fpage>
          <pub-id pub-id-type="pmid">23349802</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sref14">
          <person-group person-group-type="author">
            <name>
              <surname>Pasparakis</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Courtois</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hafner</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schmidt-Supprian</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nenci</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Toksoy</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2</article-title>
          <source>Nature</source>
          <volume>417</volume>
          <year>2002</year>
          <fpage>861</fpage>
          <lpage>866</lpage>
          <pub-id pub-id-type="pmid">12075355</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sref15">
          <person-group person-group-type="author">
            <name>
              <surname>Pasparakis</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Role of NF-kappaB in epithelial biology</article-title>
          <source>Immunol Rev</source>
          <volume>246</volume>
          <year>2012</year>
          <fpage>346</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">22435565</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="appsec1">
      <title>Appendix</title>
      <p>
        <fig id="dfig1" position="anchor">
          <label>Fig E1</label>
          <caption>
            <p><bold>A,</bold> Genealogical tree for the kindred. <italic>Arrow</italic> highlights index case. <italic>Asterisks</italic> denote family members who died within the first 2 months of life with febrile illnesses. <bold>B,</bold> Histology showing granuloma in skin by hematoxylin and eosin staining.</p>
          </caption>
          <graphic xlink:href="fx1"/>
        </fig>
        <fig id="dfig2" position="anchor">
          <label>Fig E2</label>
          <caption>
            <p><bold>A,</bold> Schematic <italic>IKBKB</italic> gene showing the mutation identified in our family. <bold>B,</bold> Sequence data for the index case, parents, and healthy control showing heterozygous carriage of the c.321C&gt;A mutation in both parents.</p>
          </caption>
          <graphic xlink:href="fx2"/>
        </fig>
        <table-wrap id="tblE1" position="anchor">
          <label>Table E1</label>
          <caption>
            <p>Rare coding homozygous variants found by exome sequencing</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th>Chr</th>
                <th>Position</th>
                <th>Ref/Obs</th>
                <th>Transcript</th>
                <th>cDNA (change)</th>
                <th>Gene</th>
                <th>Amino acid</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>1</td>
                <td>109,276,144</td>
                <td>&#x2014;/T</td>
                <td>ENST00000370017</td>
                <td>c.2130_2131insT (frameshift insertion)</td>
                <td>FNDC7 (fibronectin type III domain containing 7)</td>
                <td>p.K710fs</td>
              </tr>
              <tr>
                <td>1</td>
                <td>116,280,898</td>
                <td>C/T</td>
                <td>ENST00000261448</td>
                <td>c.G479A (nsSNV)</td>
                <td>CASQ2 (calsequestrin 2)</td>
                <td>p.R160H</td>
              </tr>
              <tr>
                <td>1</td>
                <td>120,168,566</td>
                <td>G/A</td>
                <td>ENST00000421812</td>
                <td>c.C158T (nsSNV)</td>
                <td>ZNF697 (zinc finger protein 697)</td>
                <td>p.P53L</td>
              </tr>
              <tr>
                <td>2</td>
                <td>216,197,149</td>
                <td>A/G</td>
                <td>ENST00000236959</td>
                <td>c.A733G (nsSNV)</td>
                <td>ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase)</td>
                <td>p.N245D</td>
              </tr>
              <tr>
                <td>8</td>
                <td>42,150,963</td>
                <td>C/A</td>
                <td>ENST00000520810</td>
                <td>c.C321A (stopgain SNV)</td>
                <td>IKBKB (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta)</td>
                <td>p.Y107X</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
    </sec>
    <fn-group>
      <fn id="d32e359">
        <label>&#x2606;</label>
        <p>This is an open access article under the CC BY license&#xA0;(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/" id="ccintref0005">http://creativecommons.org/licenses/by/3.0/</ext-link>).</p>
      </fn>
      <fn id="d32e367">
        <p>This work was supported by the <funding-source id="gs1">Higher Education Funding Council for England</funding-source> (to S.O.B.), <funding-source id="gs2">The Wellcome Trust</funding-source> (grant no. 095198/Z/10/Z to S.N. and grant no. 090233/Z/09/Z to A.J.T.), <funding-source id="gs3">The European Research Council</funding-source> (Starting grant 260477 to S.N.), the <funding-source id="gs4">European Union</funding-source> (FP7 collaborative grant 261441 PEVNET project to S.N.), the <funding-source id="gs5">National Institute for Health Research Cambridge Biomedical Research Centre</funding-source> (to S.N. and R.D.), <funding-source id="gs6">Great Ormond Street Hospital Children's Charity</funding-source> (to H.B.G. and F.H.), the <funding-source id="gs7">National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre</funding-source> (to K.C.G.), and the <funding-source id="gs8">National Institute for Health Research University College London Hospitals Biomedical Research Centre</funding-source> (to S.O.B.).</p>
      </fn>
      <fn id="d32e408">
        <p>Disclosure of potential conflict of interest: S. O. Burns has received research support from the <funding-source id="gs9">Higher Education Funding Council for England</funding-source> and the <funding-source id="gs10">National Institute for Health Research University College London Hospitals Biomedical Research Centre</funding-source>. A. M. Jones has received an honorarium from CSL-Behring for a lecture on subcutaneous immunoglobulin therapy and has received travel support from CSL-Behring for the 2013 AAAAI meeting. S. Nejentsev has received research support from the <funding-source id="gs11">Wellcome Trust</funding-source>, the <funding-source id="gs12">European Research Council</funding-source>, and the <funding-source id="gs13">National Institute for Health Research</funding-source>. The rest of the authors declare that they have no relevant conflicts of interest.</p>
      </fn>
    </fn-group>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig 1</label>
      <caption>
        <p><bold>A</bold> and <bold>B,</bold> Photographs showing conical teeth, hepatosplenomegally, and widespread rash. <bold>C,</bold> Quantitation of cytokine release from patient and healthy control PBMCs following <italic>in&#xA0;vitro</italic> activation with various stimuli <italic>(y-axis)</italic>. Representative data from 1 of 2 repeat experiments are shown. <bold>D,</bold> Sequence data for the index case showing the homozygous c.321C&gt;A mutation. <bold>E,</bold> Western blot showing that the IKK&#x3B2; protein is present in the healthy donor (HD) but is absent from the patient's <italic>(P)</italic> PBMCs.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table I</label>
      <caption>
        <p>Immunology investigations</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th>Cell type</th>
            <th>Patient's (age 20 mo) results</th>
            <th>Age-matched control range</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>White cell count</td>
            <td>8.42 &#xD7; 10<sup>9</sup>/L</td>
            <td>(5.0-15.0) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>Neutrophil count</td>
            <td>3.87 &#xD7; 10<sup>9</sup>/L</td>
            <td>(1.0-8.5) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>Lymphocyte count</td>
            <td>4.03 &#xD7; 10<sup>9</sup>/L</td>
            <td>(3.0-13.5) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>CD3 T cells</td>
            <td>89.0%, 3.37 &#xD7; 10<sup>9</sup>/L</td>
            <td>39%-73%, (1.8-8.0) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>CD19 B cells</td>
            <td>7.0%, 0.27 &#xD7; 10<sup>9</sup>/L</td>
            <td>17%-41%, (0.6-3.1) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>CD16<sup>+</sup>CD56<sup>+</sup> natural killer cells</td>
            <td>3.0%, 0.11 &#xD7; 10<sup>9</sup>/L</td>
            <td>3%-16%, (0.1-1.4) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>CD3<sup>+</sup>CD4<sup>+</sup> T cells</td>
            <td>61.0%, 2.31 &#xD7; 10<sup>9</sup>/L</td>
            <td>25%-50%, (0.9-5.5) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>CD3<sup>+</sup>CD8<sup>+</sup> T cells</td>
            <td>27.0%, 1.02 &#xD7; 10<sup>9</sup>/L</td>
            <td>11%-32%, (0.4-2.3) &#xD7; 10<sup>9</sup>/L</td>
          </tr>
          <tr>
            <td>Naive T cells (CD4<sup>+</sup>CD45RA<sup>+</sup>CD27<sup>+</sup>)</td>
            <td>90.0%</td>
            <td>62%-90%</td>
          </tr>
          <tr>
            <td>Naive T cells (CD8<sup>+</sup>CD45RA<sup>+</sup>CD27<sup>+</sup>)</td>
            <td>98.0%</td>
            <td>46%-85%</td>
          </tr>
          <tr>
            <td>Naive B cells (CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>&#x2212;</sup>)</td>
            <td>98.0%<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>42.6%-82.3%</td>
          </tr>
          <tr>
            <td>Nonswitched memory B cells (CD19<sup>+</sup>IgD<sup>+</sup>CD27<sup>+</sup>)</td>
            <td>1.0%<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>7.4%-32.5%</td>
          </tr>
          <tr>
            <td>Class switched memory B cells (CD19<sup>+</sup>IgD<sup>&#x2212;</sup>CD27<sup>+</sup>)</td>
            <td>0.2%<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>6.5%-29.1%</td>
          </tr>
          <tr>
            <td>Transitional B cells (CD19<sup>+</sup>IgM<sup>++</sup>CD38<sup>++</sup>)</td>
            <td>6.0%<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>0.6%-3.4%</td>
          </tr>
          <tr>
            <td>Plasmablasts (CD19<sup>+</sup>CD38<sup>++</sup>IgMwk)</td>
            <td>0.0%<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>0.4%-3.6%</td>
          </tr>
          <tr>
            <td>CD21 low B cells (CD19<sup>+</sup>CD21wkCD38wk)</td>
            <td>2.0%</td>
            <td>0.9%-7.6%</td>
          </tr>
          <tr>
            <td>IgM/IgD B cells</td>
            <td>Present</td>
            <td>Present</td>
          </tr>
          <tr>
            <td>IgG</td>
            <td>6.37 g/L after IVIG</td>
            <td>3.1-13.8 g/L</td>
          </tr>
          <tr>
            <td>IgA</td>
            <td>&lt;0.23 g/L<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>0.3-1.2 g/L</td>
          </tr>
          <tr>
            <td>IgM</td>
            <td>3.57 g/L<xref rid="tbl1fnlowast" ref-type="table-fn">&#x2217;</xref></td>
            <td>0.5-2.2 g/L</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><italic>IVIG</italic>, Intravenous immunoglobulin therapy.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tbl1fnlowast">
          <label>&#x2217;</label>
          <p>Abnormal result.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
